ArticleEmerging microbes & infections2025
SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Orally Bioavailable SARS-CoV-2 Protease Inhibitors Bearing a Hydroxymethyl Ketone Warhead.Viruses · 2026Article
- Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics.Small science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 main protease (Mpro) inhibitors are the first-line COVID-19 treatment. Nirmatrelvir is used worldwide, while ensitrelvir, licensed in Japan and Singapore, has received FDA fast-track designation. To facilitate population monitoring for viral resistance and guide next-generation inhibitor design, we investigated SARS-CoV-2 resistance and cross-resistance to ensitrelvir and nirmatrelvir. SARS-CoV-2 escape variants with high fitness and high ensitrelvir resistance were selected under clinically relevant concentrations in infectious cell culture assays. Using infectious cell culture, replicon, and Mpro assays, reverse genetics revealed synergistic combinations of resistance-associated substitutions (RAS), specifically M49L + S144A and M49L + S144A + T169I, that conferred high resistance with a low fitness cost. Molecular dynamics simulations confirmed that M49L + S144A or M49L + S144A + T169I weakened ensitrelvir-Mpro binding. M49L + S144A and M49L + S144A + T169I exhibited a lower fitness cost and conferred higher resistance than the previously identified ensitrelvir RAS M49L + E166A. Cross-resistance between these ensitrelvir RAS and previously described nirmatrelvir RAS L50F + E166V was asymmetrical, with nirmatrelvir RAS showing greater resistance to ensitrelvir than vice versa. Amino acid changes at Mpro-position 166, an emerging resistance hotspot with natural variation, had differential impacts on viral fitness and Mpro inhibitor resistance in infectious cell culture assays. The most frequently naturally occurring substitution, E166Q, did not confer significant resistance to either ensitrelvir or nirmatrelvir. However, the second most frequent substitution, E166H, conferred high resistance to nirmatrelvir, but not to ensitrelvir. This comparative resistance analysis can inform COVID-19 treatment strategies and contribute to pandemic preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.